NASDAQ · UPC
Universe Pharmaceuticals financials
$4.52−5.83%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Sep 30 | FY24 Sep 30 | FY23 Sep 30 | FY22 Sep 30 | FY21 Sep 30 |
|---|---|---|---|---|---|
| Revenue | $17.86B | $23.02B | $32.31B | $40.1M | $48.0M |
| Gross profit | $6.30B | $6.07B | $10.32B | $21.9M | $25.3M |
| Gross margin | 35.3% | 26.4% | 31.9% | 54.5% | 52.8% |
| Operating income | -$2.92B | -$8.02B | -$3.97B | -$7.0M | $13.5M |
| Net income | -$3.67B | -$8.73B | -$6.58B | -$7.9M | $11.3M |
| Net margin | −20.6% | −37.9% | −20.4% | −19.7% | 23.6% |
| Diluted EPS | $-8.06 | $-626.96 | $-1089.21 | $-1309.11 | $2148.00 |
| EBITDA | -$2.40B | -$7.53B | -$3.46B | -$6.5M | $14.0M |
| Operating cash flow | -$5.05B | -$9.51B | $1.12B | -$1.3M | -$2.1M |
| Free cash flow | -$5.32B | -$9.75B | $1.07B | -$1.4M | -$2.5M |
| Diluted shares | 455.9M | 13.9M | 6.0M | 0.0M | 0.0M |
Balance sheet
| Period end | Sep 30 | Sep 30 | Sep 30 | Sep 30 | Sep 30 |
|---|---|---|---|---|---|
| Cash & equivalents | $33.59B | $29.50B | $5.3M | $5.7M | $8.1M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $13.1M | $13.7M |
| Total debt | $9.26B | $7.99B | $5.5M | $3.9M | $4.3M |
| Total assets | $69.30B | $67.95B | $41.7M | $59.5M | $70.1M |
| Total liabilities | $13.17B | $22.45B | $13.8M | $13.1M | $11.2M |
| Shareholders' equity | $56.13B | $45.50B | $28.0M | $46.4M | $58.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology